catalyx space | $5,400,000 | (Nov 4, 2025)
Indomo | $25,000,000 | (Nov 4, 2025)
xMEMS | $21,000,000 | (Nov 4, 2025)
Vicebio
United Kingdom
- Londres, Angleterre, Royaume-Uni
- 24/09/2024
- Series B
- $100,000,000
Vicebio uses the molecular clamp technology to develop innovative vaccines against life-threatening respiratory viruses. The Molecular Clamp technology provide unique stabilisation of viral envelop glycoproteins making possible highly effective, ready-to-use, and multivalent single shot respiratory virus vaccines.
- Industry Biotechnology Research
- Website https://vicebio.com/
- LinkedIn https://www.linkedin.com/company/vicebio/
Related People
Emmanuel HanonFounder
Belgium -
Brussels Metropolitan Area
Research & Development leader, C-level Executive, with more than 20 years experience at GSK, last 7 years running the global vaccines RD for GSK. Led the discovery and development of five major Vaccines : Quadrivalent Influenza (Fluarix and Flulaval Quadrivalent), Shingles (Shingrix), Malaria (Mosquirix), RSV older adult, and MenABCWY 5-in-1 Vaccines.
Broad functional leadership experience includes R&D, medical, clinical, regulatory, technical CMC, manufacturing and quality operations. Expert in Immunology, Microbiology, and Vaccinology
Cephia AI | $4,000,000 | (Nov 4, 2025)
Ornn | $5,700,000 | (Nov 4, 2025)
Popai Health | $11,000,000 | (Nov 4, 2025)
Helex | $3,500,000 | (Nov 4, 2025)
AUI™ (Augmented Intelligence) | $20,000,000 | (Nov 4, 2025)
Mem0 | $24,000,000 | (Oct 30, 2025)
FrontlineIQ | $3,300,000 | (Oct 30, 2025)